glp-1 news oct 21 2025 ISPOR 2025: Exploring reasons for discontinuation Body-wide multi-omic counteraction of aging
Description
A critical analysis of recent literature highlights the importance of integrative and cautious approaches that account for the developmental plasticity of the pediatric organism and the possible pleiotropic effects of early pharmacological intervention.
Recent prescribing patterns underscore this trend
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
SMGT-GLP-1 Nano Microneedle Patch
Gut Health with Akkermansia &
Welcome to our shop 1
